Quick Facts
Plain-English Summary
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH), the endogenous neuropeptide that regulates skin pigmentation, sexual function, appetite, and energy balance in mammals. It was developed in the 1980s by Victor J. Hruby, Mac E. Hadley, and colleagues at the University of Arizona as part of a broader melanotropin research programme investigating structure-activity relationships of the melanocortin system. Unlike endogenous α-MSH, which is rapidly degraded in circulation, MT-II was designed with a cyclic lactam bridge between aspartate and lysine residues — a structural modification that substantially increases metabolic stability and receptor binding potency.
MT-II acts as a non-selective agonist at multiple melanocortin receptor subtypes. Its principal pharmacological effects arise from three receptor interactions: MC1R activation in skin melanocytes drives melanogenesis and produces the tanning effect for which MT-II became widely known in non-research communities; MC4R activation in the hypothalamus and spinal cord produces erectile response in males and spontaneous sexual arousal in both sexes — the effect that drove the compound's primary off-label use; and MC3R activation influences energy homeostasis and appetite suppression, though this effect has received less clinical attention.
Critically, Melanotan II directly led to the development of PT-141 (Bremelanotide), which was created by modifying MT-II's structure specifically to preserve sexual function activity while reducing unwanted side effects. PT-141, marketed as Vyleesi, received FDA approval in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the only FDA-approved compound derived from the Melanotan research lineage. MT-II itself has never completed the clinical development path required for regulatory approval and remains unapproved for any indication.
MT-II's non-selectivity across melanocortin receptor subtypes is the source of both its range of effects and its principal safety concerns. While PT-141 was refined to improve selectivity, MT-II activates MC1R, MC3R, and MC4R with limited discrimination — producing simultaneous pigmentary, sexual, cardiovascular, and gastrointestinal effects that complicate its safety profile.
Small published human pilot studies demonstrated measurable pigmentation increases (Dorr et al.) and penile erection in men with erectile dysfunction (Wessells et al., 1997) at doses of 0.025 mg/kg subcutaneously. These studies, though limited in size, constitute the most reliable human data available for MT-II. No large-scale randomised controlled trials have been completed for MT-II as a standalone compound. The compound's research trajectory effectively bifurcated: the sexual function pathway continued through PT-141 into approved clinical use, while the tanning application remained in an unapproved, off-label research context.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Rat — Melanogenesis | Dose-dependent melanin synthesis in skin following subcutaneous MT-II. Pigmentation onset within 24–48 hours; durability extended beyond dosing period. Foundational work establishing MC1R pharmacology as tanning mechanism. Hruby VJ et al., early characterisation ↗ | Preclinical |
| Rat — Erectile Function (MC4R) | Penile erection and yawning behaviour induced dose-dependently in male rats via intracerebroventricular and subcutaneous administration. MC4R knockout rodents showed ablated response, confirming receptor specificity. Critical preclinical basis for the PT-141 development pathway. | Preclinical |
| Rodent — Appetite / Body Weight | Acute reduction in food intake and cumulative body weight across multiple rodent models. Effect mediated by hypothalamic MC3R/MC4R. Relevant to understanding the appetite suppression reported by some human users, though no controlled human study exists for this endpoint. | Preclinical |
| Rodent — Cardiovascular | Transient blood pressure elevation and heart rate changes observed at pharmacological doses in rodent models. Attributed to MC4R-mediated sympathetic activation. Relevant to reported flushing and blood pressure effects in human users. | Preclinical |
| In vitro — Receptor Binding | Binding affinity characterisation across MC1R–MC5R confirmed non-selective agonism, with sub-nanomolar potency at MC1R and MC4R. Structure-activity relationship studies by Hruby's group established the pharmacophore critical to all subsequent melanocortin drug development. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| Wessells H et al. — Erectile Function | 10 men with psychogenic erectile dysfunction; randomised crossover, MT-II 0.025 mg/kg SC vs. placebo | — | Pilot RCT |
| Dorr RT et al. — Pigmentation | Open-label dose-escalation in fair-skinned volunteers; SC administration over multiple days; skin colorimetry endpoints | — | Pilot — Open Label |
| Wessells H et al. — Follow-up ED Trial | Extended evaluation of sexual response with MT-II; self-reported endpoints alongside NPT monitoring | — | Pilot RCT |
| All other indications | — | — | No Data |
Melanotan II has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
The most clinically significant safety concern for MT-II is stimulation of existing moles (nevi) and potential induction of new pigmented lesions via MC1R agonism. MC1R activation drives melanocyte proliferation systemically — not only in sun-exposed areas. Case reports and pharmacological reasoning support a theoretical risk of promoting growth of atypical nevi. Individuals with a history of melanoma, atypical mole syndrome, or BRCA2 mutation (which elevates melanoma risk) face heightened concern. Full-body dermatological monitoring before and during use is strongly advised in any research context. The theoretical link to melanoma promotion — while not established in controlled trials — cannot be dismissed given the mechanism.
Nausea was the most consistently reported adverse effect in published human pilot studies, occurring in 60–80% of participants at doses producing sexual or pigmentation effects. Facial flushing and warmth, attributed to MC4R-mediated vasodilation, were reported in approximately 40% of participants. Spontaneous erection in the absence of sexual intent is clinically documented and was dose-dependent. These effects were acute and resolved with compound clearance, but nausea was dose-limiting in the Dorr pigmentation study.
Transient blood pressure elevation has been documented with MT-II use in human pilot data and is consistent with the cardiovascular effects of MC4R activation and sympathetic stimulation observed in animal models. Individuals with pre-existing hypertension, cardiovascular disease, or those taking antihypertensive medication should be regarded as at elevated risk. PT-141 (Bremelanotide), despite being a related and more studied compound, carries an FDA boxed-warning precaution for blood pressure effects — underscoring the class-level cardiovascular signal relevant to MT-II.
- Personal or family history of melanoma or skin cancer
- Atypical mole syndrome or multiple dysplastic nevi
- Active or suspected malignancy of any type
- Pre-existing hypertension or cardiovascular disease
- Use of antihypertensive or vasodilatory medications
- Pregnancy or breastfeeding
- Children and adolescents
- Hormone-sensitive conditions
- No baseline dermatological assessment
Melanotan II is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of Melanotan II for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
People consistently underestimate how different MT-II is from PT-141. Yes, PT-141 was derived from it, but the refinement was specifically to address MC1R activity and the non-selectivity problem. PT-141 went through the full FDA process. MT-II never did. The fact that a descendant compound got approved doesn't retroactively validate the parent compound's safety profile — if anything, the development path of PT-141 tells you the researchers themselves considered MT-II's profile insufficient for approval as-is.
Exactly right. The MC1R activity is specifically what drives the nevi concern and it's specifically what makes MT-II a harder compound to evaluate safely. The development team had to engineer around MC1R to get a cleaner sexual-function-only profile. Using MT-II when PT-141 exists makes little pharmacological sense unless you specifically want the tanning effect — and even then, the mole proliferation risk is real enough that a dermatologist's involvement should be non-negotiable.
The nevi concern isn't hypothetical hand-waving. We know MC1R variants are associated with melanoma risk in the germline literature. We know MT-II activates MC1R potently and systemically. We know melanocytes in existing nevi express MC1R. The concern is mechanistically coherent, even if a controlled trial demonstrating causal melanoma promotion doesn't exist — and it won't, because no ethical trial would be designed that way. The absence of trial data here is not reassurance. It's just absence.
What I find underappreciated: the ~1–2 hour half-life of MT-II contrasts with a tanning effect that can persist for weeks. The downstream melanogenesis is a cell-level process that continues long after the peptide itself is cleared. This means the typical logic of "compound is out of your system quickly so side effects are short-lived" breaks down here. MC1R-driven melanocyte activation is not a reversible pharmacodynamic effect on the timescale of PK — the pigmentation and any concurrent stimulation of nevi activity persists independently of systemic drug concentration.
This is a critical point that gets missed in dosing discussions. The PK half-life and the PD duration are decoupled in a way that's unusual for peptides. You can't reason about the biological activity window from plasma clearance the way you can with most compounds.
The honest framing for MT-II in 2026: the compound's most pharmacologically credible use case — improving erectile function via MC4R — now has a better, FDA-approved option in PT-141. The tanning use case has no approved equivalent, but it's also the use case that carries the most meaningful safety concerns via MC1R. So you're left with a compound where the medically interesting application has been superseded, and the cosmetic application is the one with the most unresolved risk. That's an unusual position for a research compound to be in.